Abstract
Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non–small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.
Footnotes
-
↵* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH OCTOBER 2010.
-
No potential conflict of interest relevant to this article was reported.
-
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
Jump to section
Related Articles
Cited By...
- PET/CT for Pancreatic Malignancy: Potential and Pitfalls
- Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation
- Recommendations for the use of PET and PET-CT for radiotherapy planning in research projects
- Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments